Could IBM's Watson Make Experts Obsolete?
When IBM's Watson beat two human challengers to win the TV quiz show Jeopardy!, a collective "Wow!" was heard at just how far artificial intelligence has developed.
Joint Defense Pacts Pose Pitfalls
Facing increases in litigation and decreases in legal budgets, corporate defendants in patent and trademark lawsuits are more regularly employing a tactic most would not have dreamed of a decade ago. Rather than fight these cases single-handedly, they are joining together and hiring a single law firm to represent them as a group.
Rule 26: Major Changes For Attorneys and Experts
A major revision to the federal rules governing expert witness reports is on track to take effect in December. Lawyers and experts alike agree that the changes are long overdue.
The 2010 Expert Forecast: Surge Ahead
The New Year has barely begun, but all indications suggest 2010 will bring a surge in litigation involving major corporations. With that surge will come increasing demand for expert witnesses across a range of business-to-business disputes
The Top 10 Expert Rulings of 2009
As 2009 drew close to its end, the Supreme Court turned down an opportunity to decide a case many lawyers believed could set new precedent regarding the admissibility of expert testimony. But earlier in the year, in a key criminal case, the court affirmed the right of a defendant to confront experts who prepare prosecution evidence
Supreme Court to Review Controversial Patent Ruling
It is déjà vu all over again, as the Supreme Court once again has agreed to review a controversial patent ruling of the Federal Circuit Court of Appeals. The issue this time: whether a patent owner's rights were exhausted by a license agreement and subsequent sale of product pursuant to the license.
For Ronald Katz, Patent Litigation Pays Billions
Ronald A. Katz once predicted that he would someday become the wealthiest patent holder ever. By most estimates, he has achieved that goal – or will soon.
Daubert Ruling Could Severely Curtail Celebrex Cases
A federal judge's decision to exclude expert testimony may force hundreds of plaintiffs to drop their claims against Pfizer Inc. that the anti-inflammatory drug Celebrex caused them to suffer heart attacks or strokes.
Daubert Ruling Fuels Thimerosal Debate
A federal court ruling excluding all expert testimony that the drug-preservative thimerosal caused a minor child's autism is likely to have repercussions well beyond the case in which it came
